Currently, it costs a public bank approximately USD $2,000 to collect, test, and process a unit of cord blood for storage. In order to accept donations at no cost, public banks require income to support themselves. This income can come from federal funding, the profit margin of private banking, or from selling donated cord blood units for research. Alternatively, it can come from a combination of the above.
I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”
PALO ALTO, Calif., Dec. 21, 2022 — I Peace, Inc. has been awarded a “Special Recognition in Cell Therapy” during BioSpectrum Asia Excellence Award 2022 ceremony held in Singapore on December 2.
I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette. I Peace supports research institutions and pharmaceutical companies around the globe by providing clinical-grade iPSCs conforming with regulatory standards both in the U.S. and Japan. [Read more…]
Venture Capital Flows into the Exosome Industry Led by Industry Stalwarts
Venture capital activity within the exosome industry has gained substantial momentum in recent years, as more as more investors pursue this promising cell-free therapeutic technology. While funding events slowed in the past year and a half due to the Covid pandemic, funding events from 2016 to 2021 were particularly robust—with companies like Evox Therapeutics, ILIAS Biologics, Codiak BioSciences, ExCoBio, Evox Therapeutics, ArunA Bio, and Capricor Therapeutics leading the charge. [Read more…]
iPSirius Wins $2M Award from European Innovation Council to Develop a Novel Stem Cell Vaccine to Help Cancer Patients Worldwide
iPSirius is creating a new frontier in stem cell-based cancer therapeutics by developing a vaccine to fight aggressive tumors.
Paris, France, 19th December 2022 – iPSirius is a European immunotherapy company that is working to bring a new range of off-the-shelf vaccines to cancer patients worldwide to improve their prognosis and quality of life. iPSirius has developed a pipeline of engineered induced pluripotent stem cell (iPS) vaccines using its proprietary iPVAC technology. [Read more…]
PeptiGrowth Inc. is Launching Novel Synthetic Peptides BMP7 selective inhibitor and BMP4 selective inhibitor
December 12th, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed two novel synthetic peptides, “BMP7 selective inhibitor (product code: PG-005)” and “BMP4 selective inhibitor (product code: PG-006)”, which selectively bind and inhibit BMP7 and BMP4 respectively. We started marketing this product on December 8th, 2022. [Read more…]
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 336
- Next Page »